Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Kabi“
Suchtreffer
Begriffe & Kennungen
Bortezomib Fresenius Kabi · 4.8 · 52 System Organ Class Incidence Adverse reaction Skin and subcutaneous tissue Common Rash*, Pruritus*, Erythem
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · 53 System Organ Class Incidence Adverse reaction General disorders and Very common Pyrexia*, Fatigue, Asthenia
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · 56 Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment discontinu
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · 57 Six percent of patients had an adverse local reaction to subcutaneous administration, mostly redness. Cases
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: V
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: V
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: V
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Description of selected adverse reactions Herpes zoster virus reactivation Multiple myeloma Antiviral prophyla
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Description of selected adverse reactions Herpes zoster virus reactivation Multiple myeloma Antiviral prophyla
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Elderly MCL patients 42.9% and 10.4% of patients in the BR-CAP arm were in the range 65-74 years and ≥ 75 year
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Elderly MCL patients 42.9% and 10.4% of patients in the BR-CAP arm were in the range 65-74 years and ≥ 75 year
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Hepatitis B virus (HBV) reactivation and infection Mantle cell lymphoma HBV infection with fatal outcomes occu
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Hepatitis B virus (HBV) reactivation and infection Mantle cell lymphoma HBV infection with fatal outcomes occu
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Mantle cell lymphoma (MCL) The safety profile of bortezomib in 240 MCL patients treated with bortezomib at 1.3
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Mantle cell lymphoma (MCL) The safety profile of bortezomib in 240 MCL patients treated with bortezomib at 1.3
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Mantle cell lymphoma Antiviral prophylaxis was administered to 137 of 240 patients (57%) in the BR-CAP arm. Th
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Mantle cell lymphoma Antiviral prophylaxis was administered to 137 of 240 patients (57%) in the BR-CAP arm. Th
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Mantle cell lymphoma In study LYM-3002 in which bortezomib was administered with rituximab, cyclophosphamide,
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Mantle cell lymphoma In study LYM-3002 in which bortezomib was administered with rituximab, cyclophosphamide,
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Notable differences in the safety profile of bortezomib administered subcutaneously versus intravenously as si
Eintrag öffnen